Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 Altman Z-Score is 4.15 as of Jul. 15, 2026, which is 22% below its 10-year median of 5.33. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 953 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 59.39% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 4.17 is strong.
Birzeit Pharmaceutical Co has a Altman Z-Score of 4.15, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Birzeit Pharmaceutical Co's Altman Z-Score or its related term are showing as below:
XPAE:BPC'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.79 Med: 5.33 Max: 7
Current: 4.17
During the past 13 years, Birzeit Pharmaceutical Co's highest Altman Z-Score was 7.00. The lowest was 1.79. And the median was 5.33.
Birzeit Pharmaceutical Co (XPAE:BPC) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: Altman Z-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Altman Z-Score falls into.
Birzeit Pharmaceutical Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Altman Z-Score of 4.15 as of Jul. 15, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 22% below median its historical median of 5.33. Over the past decade, Birzeit Pharmaceutical Co's Altman Z-Score has ranged from 1.79 to 7.00. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #387 out of 953 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Birzeit Pharmaceutical Co's Altman Z-Score too high?
Birzeit Pharmaceutical Co's current Altman Z-Score of 4.15 is 22% below median its 10-year median of 5.33. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 7.00. The Drug Manufacturers industry median Altman Z-Score is 3.25. Birzeit Pharmaceutical Co's value of 4.15 is 27.7% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #387 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #387 out of 953 companies for Altman Z-Score. This puts Birzeit Pharmaceutical Co in the upper half of its industry. The industry median Altman Z-Score is 3.25. Birzeit Pharmaceutical Co's value of 4.15 is 27.7% above this benchmark. Historically, Birzeit Pharmaceutical Co's own Altman Z-Score has ranged from 1.79 to 7.00 over the past decade. While the company's 10-year median is 5.33 vs. the industry median of 3.25, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.25, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Altman Z-Score of 4.15 is 27.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Altman Z-Score is 4.15, which is 22% below median its own 10-year median of 5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Altman Z-Score is 4.15, which is 22% below median its 10-year median of 5.33 and 27.7% above the Drug Manufacturers industry median of 3.25. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Altman Z-Score is 4.15 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Altman Z-Score: 4.15 (22% below median its 10-year median of 5.33)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 27.7% above the Drug Manufacturers median (#387 of 953)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
